Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.
Identifieur interne : 000693 ( PubMed/Checkpoint ); précédent : 000692; suivant : 000694Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.
Auteurs : Lukasz Szyrwiel [France] ; J Zsef S. Pap ; Wieslaw Malinka ; Zbigniew Szewczuk ; Aleksandra Kotynia ; Justyna BrasunSource :
- Journal of pharmaceutical and biomedical analysis [ 1873-264X ] ; 2013.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : Copper, Iron, Zinc.
- chemical , pharmacology : Antiparkinson Agents, Benserazide, Levodopa.
- chemical : Drug Combinations.
- methods : Mass Spectrometry, Spectrophotometry, Ultraviolet.
Abstract
One of the treatments of Parkinson disease is based on increasing the brain dopamine level by L-DOPA (LD) applications. To prevent the peripheral degradation of levodopa, another drug, benserazide is applied. On the other hand, during this neurodegenerative disease changes in the homeostasis of metals are observed and the increasing brain zinc levels are postulated to have therapeutic effects. Here we present studies on interactions of Zn(II), Cu(II), Fe(II) ions with benserazide and with benserazide/levodopa in ternary system. By applying mass spectrometry and UV-vis methods we describe the interactions between selected metal ions and the drug additives in the investigated systems. The results show forming of equimolar complexes in the binary and ternary systems.
DOI: 10.1016/j.jpba.2012.11.032
PubMed: 23291441
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23291441Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.</title><author><name sortKey="Szyrwiel, Lukasz" sort="Szyrwiel, Lukasz" uniqKey="Szyrwiel L" first="Lukasz" last="Szyrwiel">Lukasz Szyrwiel</name><affiliation wicri:level="3"><nlm:affiliation>Department of Chemistry of Drugs, Wrocław Medical University, ul. Borowska 211, 50-552 Wrocław, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau, France. lukasz.szyrwiel@am.wroc.pl</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Chemistry of Drugs, Wrocław Medical University, ul. Borowska 211, 50-552 Wrocław, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Pau</settlement></placeName></affiliation></author><author><name sortKey="Pap, J Zsef S" sort="Pap, J Zsef S" uniqKey="Pap J" first="J Zsef S" last="Pap">J Zsef S. Pap</name></author><author><name sortKey="Malinka, Wieslaw" sort="Malinka, Wieslaw" uniqKey="Malinka W" first="Wieslaw" last="Malinka">Wieslaw Malinka</name></author><author><name sortKey="Szewczuk, Zbigniew" sort="Szewczuk, Zbigniew" uniqKey="Szewczuk Z" first="Zbigniew" last="Szewczuk">Zbigniew Szewczuk</name></author><author><name sortKey="Kotynia, Aleksandra" sort="Kotynia, Aleksandra" uniqKey="Kotynia A" first="Aleksandra" last="Kotynia">Aleksandra Kotynia</name></author><author><name sortKey="Brasun, Justyna" sort="Brasun, Justyna" uniqKey="Brasun J" first="Justyna" last="Brasun">Justyna Brasun</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23291441</idno><idno type="pmid">23291441</idno><idno type="doi">10.1016/j.jpba.2012.11.032</idno><idno type="wicri:Area/PubMed/Corpus">000758</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000758</idno><idno type="wicri:Area/PubMed/Curation">000725</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000725</idno><idno type="wicri:Area/PubMed/Checkpoint">000725</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000725</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.</title><author><name sortKey="Szyrwiel, Lukasz" sort="Szyrwiel, Lukasz" uniqKey="Szyrwiel L" first="Lukasz" last="Szyrwiel">Lukasz Szyrwiel</name><affiliation wicri:level="3"><nlm:affiliation>Department of Chemistry of Drugs, Wrocław Medical University, ul. Borowska 211, 50-552 Wrocław, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau, France. lukasz.szyrwiel@am.wroc.pl</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Chemistry of Drugs, Wrocław Medical University, ul. Borowska 211, 50-552 Wrocław, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Pau</settlement></placeName></affiliation></author><author><name sortKey="Pap, J Zsef S" sort="Pap, J Zsef S" uniqKey="Pap J" first="J Zsef S" last="Pap">J Zsef S. Pap</name></author><author><name sortKey="Malinka, Wieslaw" sort="Malinka, Wieslaw" uniqKey="Malinka W" first="Wieslaw" last="Malinka">Wieslaw Malinka</name></author><author><name sortKey="Szewczuk, Zbigniew" sort="Szewczuk, Zbigniew" uniqKey="Szewczuk Z" first="Zbigniew" last="Szewczuk">Zbigniew Szewczuk</name></author><author><name sortKey="Kotynia, Aleksandra" sort="Kotynia, Aleksandra" uniqKey="Kotynia A" first="Aleksandra" last="Kotynia">Aleksandra Kotynia</name></author><author><name sortKey="Brasun, Justyna" sort="Brasun, Justyna" uniqKey="Brasun J" first="Justyna" last="Brasun">Justyna Brasun</name></author></analytic><series><title level="j">Journal of pharmaceutical and biomedical analysis</title><idno type="eISSN">1873-264X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (pharmacology)</term><term>Benserazide (pharmacology)</term><term>Copper (metabolism)</term><term>Drug Combinations</term><term>Iron (metabolism)</term><term>Levodopa (pharmacology)</term><term>Mass Spectrometry (methods)</term><term>Spectrophotometry, Ultraviolet (methods)</term><term>Zinc (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Copper</term><term>Iron</term><term>Zinc</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mass Spectrometry</term><term>Spectrophotometry, Ultraviolet</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One of the treatments of Parkinson disease is based on increasing the brain dopamine level by L-DOPA (LD) applications. To prevent the peripheral degradation of levodopa, another drug, benserazide is applied. On the other hand, during this neurodegenerative disease changes in the homeostasis of metals are observed and the increasing brain zinc levels are postulated to have therapeutic effects. Here we present studies on interactions of Zn(II), Cu(II), Fe(II) ions with benserazide and with benserazide/levodopa in ternary system. By applying mass spectrometry and UV-vis methods we describe the interactions between selected metal ions and the drug additives in the investigated systems. The results show forming of equimolar complexes in the binary and ternary systems.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23291441</PMID><DateCreated><Year>2013</Year><Month>02</Month><Day>04</Day></DateCreated><DateCompleted><Year>2013</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-264X</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><PubDate><Year>2013</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of pharmaceutical and biomedical analysis</Title><ISOAbbreviation>J Pharm Biomed Anal</ISOAbbreviation></Journal><ArticleTitle>Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.</ArticleTitle><Pagination><MedlinePgn>36-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpba.2012.11.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0731-7085(12)00647-4</ELocationID><Abstract><AbstractText>One of the treatments of Parkinson disease is based on increasing the brain dopamine level by L-DOPA (LD) applications. To prevent the peripheral degradation of levodopa, another drug, benserazide is applied. On the other hand, during this neurodegenerative disease changes in the homeostasis of metals are observed and the increasing brain zinc levels are postulated to have therapeutic effects. Here we present studies on interactions of Zn(II), Cu(II), Fe(II) ions with benserazide and with benserazide/levodopa in ternary system. By applying mass spectrometry and UV-vis methods we describe the interactions between selected metal ions and the drug additives in the investigated systems. The results show forming of equimolar complexes in the binary and ternary systems.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szyrwiel</LastName><ForeName>Lukasz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemistry of Drugs, Wrocław Medical University, ul. Borowska 211, 50-552 Wrocław, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau, France. lukasz.szyrwiel@am.wroc.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pap</LastName><ForeName>József S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Malinka</LastName><ForeName>Wieslaw</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Szewczuk</LastName><ForeName>Zbigniew</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kotynia</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brasun</LastName><ForeName>Justyna</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pharm Biomed Anal</MedlineTA><NlmUniqueID>8309336</NlmUniqueID><ISSNLinking>0731-7085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C005177">benserazide, levodopa drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>762OS3ZEJU</RegistryNumber><NameOfSubstance UI="D001545">Benserazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001545" MajorTopicYN="N">Benserazide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013056" MajorTopicYN="N">Spectrophotometry, Ultraviolet</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23291441</ArticleId><ArticleId IdType="pii">S0731-7085(12)00647-4</ArticleId><ArticleId IdType="doi">10.1016/j.jpba.2012.11.032</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Pau</li></settlement></list><tree><noCountry><name sortKey="Brasun, Justyna" sort="Brasun, Justyna" uniqKey="Brasun J" first="Justyna" last="Brasun">Justyna Brasun</name><name sortKey="Kotynia, Aleksandra" sort="Kotynia, Aleksandra" uniqKey="Kotynia A" first="Aleksandra" last="Kotynia">Aleksandra Kotynia</name><name sortKey="Malinka, Wieslaw" sort="Malinka, Wieslaw" uniqKey="Malinka W" first="Wieslaw" last="Malinka">Wieslaw Malinka</name><name sortKey="Pap, J Zsef S" sort="Pap, J Zsef S" uniqKey="Pap J" first="J Zsef S" last="Pap">J Zsef S. Pap</name><name sortKey="Szewczuk, Zbigniew" sort="Szewczuk, Zbigniew" uniqKey="Szewczuk Z" first="Zbigniew" last="Szewczuk">Zbigniew Szewczuk</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Szyrwiel, Lukasz" sort="Szyrwiel, Lukasz" uniqKey="Szyrwiel L" first="Lukasz" last="Szyrwiel">Lukasz Szyrwiel</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000693 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000693 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23291441
|texte= Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23291441" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |